FINWIRES · TerminalLIVE
FINWIRES

Vermilion Reports Higher Q1 Production, Sales Volumes; Maintains 2026 Outlook

By

-- Vermilion Energy (VET) reported Q1 earnings on Wednesday, showing total production of 125,618 barrels of oil equivalent per day, up from 103,115 boe/d a year earlier, according to the company.

Natural gas production increased to 539.29 million cubic feet per day for the quarter ended Mar. 31 from 369.36 mmcf/d a year earlier, while natural gas liquids output rose to 12,044 b/d from 9,167 b/d, Vermilion said.

Crude oil and condensate production declined to 23,692 b/d from 32,386 b/d a year earlier, according to the company.

Vermilion generated an average production of 99,746 boe/d from Canadian operations in Q1, up 10% from the prior quarter, while international production totaled 25,872 boe/d, the company added.

Vermilion reported consolidated sales volumes of 126,867 boe/d in Q1, up from 102,427 boe/d a year earlier, the company said.

Crude oil and condensate sales volumes declined to 24,941 b/d in the quarter, compared with 31,698 b/d a year earlier, while natural gas liquids sales volumes increased to 12,044 b/d from 9,167 b/d, Vermilion said.

Natural gas sales volumes increased to 539.29 million cubic feet per day from 369.36 mmcf/d a year earlier, the company added.

Vermilion expects Q2 production to average 123,000 boe/d to 125,000 boe/d and maintains its full-year production outlook of 118,000 boe/d to 122,000 boe/d on exploration and development spending of CA$600 million ($440.2 million) to CA$630 million, according to the company.

Price: $11.82, Change: $-1.81, Percent Change: -13.28%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL